A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center

There is increasing interest regarding SARS-CoV-2 infection in patients with autoimmune and immune-mediated inflammatory diseases (AI/IMID) with some discrepancies in different cohorts about their risk and outcomes. The aim was to describe a multidisciplinary cohort of patients with AI/IMID and symp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of autoimmunity 2021-02, Vol.117, p.102580-102580, Article 102580
Hauptverfasser: Sarmiento-Monroy, Juan C., Espinosa, Gerard, Londoño, Maria-Carlota, Meira, Fernanda, Caballol, Berta, Llufriu, Sara, Carrasco, Josep Lluis, Moll-Udina, Aina, Quintana, Luis F., Giavedoni, Priscila, Ramírez, Julio, Inciarte-Mundo, Jose, Solana, Elisabeth, Blanco, Yolanda, Martinez-Hernandez, Eugenia, Sepúlveda, Maria, Llorenç, Victor, Prieto-González, Sergio, Espígol-Frigolé, Georgina, Milisenda, Jose C., Cid, Maria C., Mascaró, Jose M., Blanco, Isabel, Barberá, Joan Albert, Sibila, Oriol, Gratacos-Ginès, Jordi, Adán, Alfredo, Agustí, Alvaro, Sanmartí, Raimon, Panés, Julian, Cervera, Ricard, Vila, Jordi, Soriano, Alex, Gómez-Puerta, José A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 102580
container_issue
container_start_page 102580
container_title Journal of autoimmunity
container_volume 117
creator Sarmiento-Monroy, Juan C.
Espinosa, Gerard
Londoño, Maria-Carlota
Meira, Fernanda
Caballol, Berta
Llufriu, Sara
Carrasco, Josep Lluis
Moll-Udina, Aina
Quintana, Luis F.
Giavedoni, Priscila
Ramírez, Julio
Inciarte-Mundo, Jose
Solana, Elisabeth
Blanco, Yolanda
Martinez-Hernandez, Eugenia
Sepúlveda, Maria
Llorenç, Victor
Prieto-González, Sergio
Espígol-Frigolé, Georgina
Milisenda, Jose C.
Cid, Maria C.
Mascaró, Jose M.
Blanco, Isabel
Barberá, Joan Albert
Sibila, Oriol
Gratacos-Ginès, Jordi
Adán, Alfredo
Agustí, Alvaro
Sanmartí, Raimon
Panés, Julian
Cervera, Ricard
Vila, Jordi
Soriano, Alex
Gómez-Puerta, José A.
description There is increasing interest regarding SARS-CoV-2 infection in patients with autoimmune and immune-mediated inflammatory diseases (AI/IMID) with some discrepancies in different cohorts about their risk and outcomes. The aim was to describe a multidisciplinary cohort of patients with AI/IMID and symptomatic SARS-CoV-2 infection in a single tertiary center and analyze sociodemographic, clinical, and therapeutic factors associated with poor outcomes. A retrospective observational study was conducted from the 1st of March until May 29th, 2020 in a University tertiary hospital in Barcelona, Spain. Patients with an underlying AI/IMID and symptomatic SARS-CoV-2 infection were identified in our local SARS-CoV-2 infection database. Controls (2:1) were selected from the same database and matched by age and gender. The primary outcome was severe SARS-CoV-2 infection, which was a composite endpoint including admission to the intensive care unit (ICU), need for mechanical ventilation (MV), and/or death. Several covariates including age, sex, and comorbidities among others were combined into a multivariate model having severe SARS-CoV-2 as the dependent variable. Also, a sensitivity analysis was performed evaluating AID and IMID separately. The prevalence of symptomatic SARS-CoV-2 infection in a cohort of AI/IMID patients was 1.3%. Eighty-five patients with AI/IMID and symptomatic SARS-CoV-2 were identified, requiring hospitalization in 58 (68%) cases. A total of 175 patients admitted for SARS-CoV-2 (58 with AI/IMID and 117 matched-controls) were analyzed. In logistic regression analysis, a significant inverse association between AI/IMID group and severe SARS-CoV-2 (OR 0.28; 95% CI 0.12–0.61; p = 0.001), need of MV (OR 0.20; IC 95% 0.05–0.71; p = 0.014), and ICU admission (OR 0.25; IC 95% 0.10–0.62; p = 0.003) was found. Patients with AI/IMID who require admission for SARS-CoV-2 infection have a lower risk of developing severe disease, including the need to stay in the ICU and MV. •Patients with AI/IMID fwho required admission for SARS CoV2 infection have a lower risk of developing severe disease.•Among patients with AID and IMID, there were no differences in terms of severity.•According to the 7-category ordinal scale, maximum oxygen requirement was lower among AI/IMID group.
doi_str_mv 10.1016/j.jaut.2020.102580
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7836738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0896841120302134</els_id><sourcerecordid>2471461730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-c81a0f3f1fce23d965e2b1c4b9cc622b0cbf75a8b48ccd4f3fc3e6351d821d933</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1ERZfCH-CAfOSSxR9x4kgIqVqgrVSpl8LVcpzJ1qs4DrbTqnd-OI6yVPRSXzwav_POeB6EPlCypYRWnw_bg57TlhG2JJiQ5BXaUNKIoqGifo02RDZVIUtKT9HbGA-EUCqEeINOeT6yJvUG_TnHbh6S7Ww0dhrsqMMjDrC3MeXA93jSycKYIn6w6Q7nft46N4-A9djhNSwcdFYn6HB2AR3hKI6PbkreZQODdze_rr4VtMF98A5rHO24HwCbbA3hHTrp9RDh_fE-Qz9_fL_dXRbXNxdXu_PrwpRCpMJIqknPe9obYLxrKgGspaZsG2Mqxlpi2r4WWralNKYrs9JwqLignWS0azg_Q19X32lu88xL86AHNQXr8reV11Y9fxntndr7e1VLXtVcZoNPR4Pgf88Qk3J5bzAMegQ_R8XKmpYVrTnJUrZKTfAxBuif2lCiFnzqoBZ8asGnVny56OP_Az6V_OOVBV9WAeQ13VsIKmOD0WQAAUxSnbcv-f8Fe--wLw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471461730</pqid></control><display><type>article</type><title>A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sarmiento-Monroy, Juan C. ; Espinosa, Gerard ; Londoño, Maria-Carlota ; Meira, Fernanda ; Caballol, Berta ; Llufriu, Sara ; Carrasco, Josep Lluis ; Moll-Udina, Aina ; Quintana, Luis F. ; Giavedoni, Priscila ; Ramírez, Julio ; Inciarte-Mundo, Jose ; Solana, Elisabeth ; Blanco, Yolanda ; Martinez-Hernandez, Eugenia ; Sepúlveda, Maria ; Llorenç, Victor ; Prieto-González, Sergio ; Espígol-Frigolé, Georgina ; Milisenda, Jose C. ; Cid, Maria C. ; Mascaró, Jose M. ; Blanco, Isabel ; Barberá, Joan Albert ; Sibila, Oriol ; Gratacos-Ginès, Jordi ; Adán, Alfredo ; Agustí, Alvaro ; Sanmartí, Raimon ; Panés, Julian ; Cervera, Ricard ; Vila, Jordi ; Soriano, Alex ; Gómez-Puerta, José A.</creator><creatorcontrib>Sarmiento-Monroy, Juan C. ; Espinosa, Gerard ; Londoño, Maria-Carlota ; Meira, Fernanda ; Caballol, Berta ; Llufriu, Sara ; Carrasco, Josep Lluis ; Moll-Udina, Aina ; Quintana, Luis F. ; Giavedoni, Priscila ; Ramírez, Julio ; Inciarte-Mundo, Jose ; Solana, Elisabeth ; Blanco, Yolanda ; Martinez-Hernandez, Eugenia ; Sepúlveda, Maria ; Llorenç, Victor ; Prieto-González, Sergio ; Espígol-Frigolé, Georgina ; Milisenda, Jose C. ; Cid, Maria C. ; Mascaró, Jose M. ; Blanco, Isabel ; Barberá, Joan Albert ; Sibila, Oriol ; Gratacos-Ginès, Jordi ; Adán, Alfredo ; Agustí, Alvaro ; Sanmartí, Raimon ; Panés, Julian ; Cervera, Ricard ; Vila, Jordi ; Soriano, Alex ; Gómez-Puerta, José A. ; Immunocovid Clinic</creatorcontrib><description>There is increasing interest regarding SARS-CoV-2 infection in patients with autoimmune and immune-mediated inflammatory diseases (AI/IMID) with some discrepancies in different cohorts about their risk and outcomes. The aim was to describe a multidisciplinary cohort of patients with AI/IMID and symptomatic SARS-CoV-2 infection in a single tertiary center and analyze sociodemographic, clinical, and therapeutic factors associated with poor outcomes. A retrospective observational study was conducted from the 1st of March until May 29th, 2020 in a University tertiary hospital in Barcelona, Spain. Patients with an underlying AI/IMID and symptomatic SARS-CoV-2 infection were identified in our local SARS-CoV-2 infection database. Controls (2:1) were selected from the same database and matched by age and gender. The primary outcome was severe SARS-CoV-2 infection, which was a composite endpoint including admission to the intensive care unit (ICU), need for mechanical ventilation (MV), and/or death. Several covariates including age, sex, and comorbidities among others were combined into a multivariate model having severe SARS-CoV-2 as the dependent variable. Also, a sensitivity analysis was performed evaluating AID and IMID separately. The prevalence of symptomatic SARS-CoV-2 infection in a cohort of AI/IMID patients was 1.3%. Eighty-five patients with AI/IMID and symptomatic SARS-CoV-2 were identified, requiring hospitalization in 58 (68%) cases. A total of 175 patients admitted for SARS-CoV-2 (58 with AI/IMID and 117 matched-controls) were analyzed. In logistic regression analysis, a significant inverse association between AI/IMID group and severe SARS-CoV-2 (OR 0.28; 95% CI 0.12–0.61; p = 0.001), need of MV (OR 0.20; IC 95% 0.05–0.71; p = 0.014), and ICU admission (OR 0.25; IC 95% 0.10–0.62; p = 0.003) was found. Patients with AI/IMID who require admission for SARS-CoV-2 infection have a lower risk of developing severe disease, including the need to stay in the ICU and MV. •Patients with AI/IMID fwho required admission for SARS CoV2 infection have a lower risk of developing severe disease.•Among patients with AID and IMID, there were no differences in terms of severity.•According to the 7-category ordinal scale, maximum oxygen requirement was lower among AI/IMID group.</description><identifier>ISSN: 0896-8411</identifier><identifier>ISSN: 1095-9157</identifier><identifier>EISSN: 1095-9157</identifier><identifier>DOI: 10.1016/j.jaut.2020.102580</identifier><identifier>PMID: 33338707</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adverse outcome ; Aged ; Autoimmune diseases ; Autoimmune Diseases - epidemiology ; Autoimmune Diseases - mortality ; Cohort Studies ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - mortality ; Female ; Hospitalization - statistics &amp; numerical data ; Humans ; Immunosuppression ; Intensive Care Units - statistics &amp; numerical data ; Interdisciplinary Communication ; Male ; Middle Aged ; Prevalence ; Registries ; Respiration, Artificial - statistics &amp; numerical data ; Retrospective Studies ; Risk Factors ; SARS-CoV-2 - physiology ; Severe acute respiratory syndrome coronavirus 2 ; Spain - epidemiology ; Survival Analysis ; Treatment Outcome</subject><ispartof>Journal of autoimmunity, 2021-02, Vol.117, p.102580-102580, Article 102580</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-c81a0f3f1fce23d965e2b1c4b9cc622b0cbf75a8b48ccd4f3fc3e6351d821d933</citedby><cites>FETCH-LOGICAL-c455t-c81a0f3f1fce23d965e2b1c4b9cc622b0cbf75a8b48ccd4f3fc3e6351d821d933</cites><orcidid>0000-0001-8177-702X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaut.2020.102580$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33338707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarmiento-Monroy, Juan C.</creatorcontrib><creatorcontrib>Espinosa, Gerard</creatorcontrib><creatorcontrib>Londoño, Maria-Carlota</creatorcontrib><creatorcontrib>Meira, Fernanda</creatorcontrib><creatorcontrib>Caballol, Berta</creatorcontrib><creatorcontrib>Llufriu, Sara</creatorcontrib><creatorcontrib>Carrasco, Josep Lluis</creatorcontrib><creatorcontrib>Moll-Udina, Aina</creatorcontrib><creatorcontrib>Quintana, Luis F.</creatorcontrib><creatorcontrib>Giavedoni, Priscila</creatorcontrib><creatorcontrib>Ramírez, Julio</creatorcontrib><creatorcontrib>Inciarte-Mundo, Jose</creatorcontrib><creatorcontrib>Solana, Elisabeth</creatorcontrib><creatorcontrib>Blanco, Yolanda</creatorcontrib><creatorcontrib>Martinez-Hernandez, Eugenia</creatorcontrib><creatorcontrib>Sepúlveda, Maria</creatorcontrib><creatorcontrib>Llorenç, Victor</creatorcontrib><creatorcontrib>Prieto-González, Sergio</creatorcontrib><creatorcontrib>Espígol-Frigolé, Georgina</creatorcontrib><creatorcontrib>Milisenda, Jose C.</creatorcontrib><creatorcontrib>Cid, Maria C.</creatorcontrib><creatorcontrib>Mascaró, Jose M.</creatorcontrib><creatorcontrib>Blanco, Isabel</creatorcontrib><creatorcontrib>Barberá, Joan Albert</creatorcontrib><creatorcontrib>Sibila, Oriol</creatorcontrib><creatorcontrib>Gratacos-Ginès, Jordi</creatorcontrib><creatorcontrib>Adán, Alfredo</creatorcontrib><creatorcontrib>Agustí, Alvaro</creatorcontrib><creatorcontrib>Sanmartí, Raimon</creatorcontrib><creatorcontrib>Panés, Julian</creatorcontrib><creatorcontrib>Cervera, Ricard</creatorcontrib><creatorcontrib>Vila, Jordi</creatorcontrib><creatorcontrib>Soriano, Alex</creatorcontrib><creatorcontrib>Gómez-Puerta, José A.</creatorcontrib><creatorcontrib>Immunocovid Clinic</creatorcontrib><title>A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center</title><title>Journal of autoimmunity</title><addtitle>J Autoimmun</addtitle><description>There is increasing interest regarding SARS-CoV-2 infection in patients with autoimmune and immune-mediated inflammatory diseases (AI/IMID) with some discrepancies in different cohorts about their risk and outcomes. The aim was to describe a multidisciplinary cohort of patients with AI/IMID and symptomatic SARS-CoV-2 infection in a single tertiary center and analyze sociodemographic, clinical, and therapeutic factors associated with poor outcomes. A retrospective observational study was conducted from the 1st of March until May 29th, 2020 in a University tertiary hospital in Barcelona, Spain. Patients with an underlying AI/IMID and symptomatic SARS-CoV-2 infection were identified in our local SARS-CoV-2 infection database. Controls (2:1) were selected from the same database and matched by age and gender. The primary outcome was severe SARS-CoV-2 infection, which was a composite endpoint including admission to the intensive care unit (ICU), need for mechanical ventilation (MV), and/or death. Several covariates including age, sex, and comorbidities among others were combined into a multivariate model having severe SARS-CoV-2 as the dependent variable. Also, a sensitivity analysis was performed evaluating AID and IMID separately. The prevalence of symptomatic SARS-CoV-2 infection in a cohort of AI/IMID patients was 1.3%. Eighty-five patients with AI/IMID and symptomatic SARS-CoV-2 were identified, requiring hospitalization in 58 (68%) cases. A total of 175 patients admitted for SARS-CoV-2 (58 with AI/IMID and 117 matched-controls) were analyzed. In logistic regression analysis, a significant inverse association between AI/IMID group and severe SARS-CoV-2 (OR 0.28; 95% CI 0.12–0.61; p = 0.001), need of MV (OR 0.20; IC 95% 0.05–0.71; p = 0.014), and ICU admission (OR 0.25; IC 95% 0.10–0.62; p = 0.003) was found. Patients with AI/IMID who require admission for SARS-CoV-2 infection have a lower risk of developing severe disease, including the need to stay in the ICU and MV. •Patients with AI/IMID fwho required admission for SARS CoV2 infection have a lower risk of developing severe disease.•Among patients with AID and IMID, there were no differences in terms of severity.•According to the 7-category ordinal scale, maximum oxygen requirement was lower among AI/IMID group.</description><subject>Adverse outcome</subject><subject>Aged</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - epidemiology</subject><subject>Autoimmune Diseases - mortality</subject><subject>Cohort Studies</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - mortality</subject><subject>Female</subject><subject>Hospitalization - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Intensive Care Units - statistics &amp; numerical data</subject><subject>Interdisciplinary Communication</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Registries</subject><subject>Respiration, Artificial - statistics &amp; numerical data</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>SARS-CoV-2 - physiology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spain - epidemiology</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0896-8411</issn><issn>1095-9157</issn><issn>1095-9157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi1ERZfCH-CAfOSSxR9x4kgIqVqgrVSpl8LVcpzJ1qs4DrbTqnd-OI6yVPRSXzwav_POeB6EPlCypYRWnw_bg57TlhG2JJiQ5BXaUNKIoqGifo02RDZVIUtKT9HbGA-EUCqEeINOeT6yJvUG_TnHbh6S7Ww0dhrsqMMjDrC3MeXA93jSycKYIn6w6Q7nft46N4-A9djhNSwcdFYn6HB2AR3hKI6PbkreZQODdze_rr4VtMF98A5rHO24HwCbbA3hHTrp9RDh_fE-Qz9_fL_dXRbXNxdXu_PrwpRCpMJIqknPe9obYLxrKgGspaZsG2Mqxlpi2r4WWralNKYrs9JwqLignWS0azg_Q19X32lu88xL86AHNQXr8reV11Y9fxntndr7e1VLXtVcZoNPR4Pgf88Qk3J5bzAMegQ_R8XKmpYVrTnJUrZKTfAxBuif2lCiFnzqoBZ8asGnVny56OP_Az6V_OOVBV9WAeQ13VsIKmOD0WQAAUxSnbcv-f8Fe--wLw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Sarmiento-Monroy, Juan C.</creator><creator>Espinosa, Gerard</creator><creator>Londoño, Maria-Carlota</creator><creator>Meira, Fernanda</creator><creator>Caballol, Berta</creator><creator>Llufriu, Sara</creator><creator>Carrasco, Josep Lluis</creator><creator>Moll-Udina, Aina</creator><creator>Quintana, Luis F.</creator><creator>Giavedoni, Priscila</creator><creator>Ramírez, Julio</creator><creator>Inciarte-Mundo, Jose</creator><creator>Solana, Elisabeth</creator><creator>Blanco, Yolanda</creator><creator>Martinez-Hernandez, Eugenia</creator><creator>Sepúlveda, Maria</creator><creator>Llorenç, Victor</creator><creator>Prieto-González, Sergio</creator><creator>Espígol-Frigolé, Georgina</creator><creator>Milisenda, Jose C.</creator><creator>Cid, Maria C.</creator><creator>Mascaró, Jose M.</creator><creator>Blanco, Isabel</creator><creator>Barberá, Joan Albert</creator><creator>Sibila, Oriol</creator><creator>Gratacos-Ginès, Jordi</creator><creator>Adán, Alfredo</creator><creator>Agustí, Alvaro</creator><creator>Sanmartí, Raimon</creator><creator>Panés, Julian</creator><creator>Cervera, Ricard</creator><creator>Vila, Jordi</creator><creator>Soriano, Alex</creator><creator>Gómez-Puerta, José A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8177-702X</orcidid></search><sort><creationdate>20210201</creationdate><title>A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center</title><author>Sarmiento-Monroy, Juan C. ; Espinosa, Gerard ; Londoño, Maria-Carlota ; Meira, Fernanda ; Caballol, Berta ; Llufriu, Sara ; Carrasco, Josep Lluis ; Moll-Udina, Aina ; Quintana, Luis F. ; Giavedoni, Priscila ; Ramírez, Julio ; Inciarte-Mundo, Jose ; Solana, Elisabeth ; Blanco, Yolanda ; Martinez-Hernandez, Eugenia ; Sepúlveda, Maria ; Llorenç, Victor ; Prieto-González, Sergio ; Espígol-Frigolé, Georgina ; Milisenda, Jose C. ; Cid, Maria C. ; Mascaró, Jose M. ; Blanco, Isabel ; Barberá, Joan Albert ; Sibila, Oriol ; Gratacos-Ginès, Jordi ; Adán, Alfredo ; Agustí, Alvaro ; Sanmartí, Raimon ; Panés, Julian ; Cervera, Ricard ; Vila, Jordi ; Soriano, Alex ; Gómez-Puerta, José A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-c81a0f3f1fce23d965e2b1c4b9cc622b0cbf75a8b48ccd4f3fc3e6351d821d933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse outcome</topic><topic>Aged</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - epidemiology</topic><topic>Autoimmune Diseases - mortality</topic><topic>Cohort Studies</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - mortality</topic><topic>Female</topic><topic>Hospitalization - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Intensive Care Units - statistics &amp; numerical data</topic><topic>Interdisciplinary Communication</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Registries</topic><topic>Respiration, Artificial - statistics &amp; numerical data</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>SARS-CoV-2 - physiology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spain - epidemiology</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarmiento-Monroy, Juan C.</creatorcontrib><creatorcontrib>Espinosa, Gerard</creatorcontrib><creatorcontrib>Londoño, Maria-Carlota</creatorcontrib><creatorcontrib>Meira, Fernanda</creatorcontrib><creatorcontrib>Caballol, Berta</creatorcontrib><creatorcontrib>Llufriu, Sara</creatorcontrib><creatorcontrib>Carrasco, Josep Lluis</creatorcontrib><creatorcontrib>Moll-Udina, Aina</creatorcontrib><creatorcontrib>Quintana, Luis F.</creatorcontrib><creatorcontrib>Giavedoni, Priscila</creatorcontrib><creatorcontrib>Ramírez, Julio</creatorcontrib><creatorcontrib>Inciarte-Mundo, Jose</creatorcontrib><creatorcontrib>Solana, Elisabeth</creatorcontrib><creatorcontrib>Blanco, Yolanda</creatorcontrib><creatorcontrib>Martinez-Hernandez, Eugenia</creatorcontrib><creatorcontrib>Sepúlveda, Maria</creatorcontrib><creatorcontrib>Llorenç, Victor</creatorcontrib><creatorcontrib>Prieto-González, Sergio</creatorcontrib><creatorcontrib>Espígol-Frigolé, Georgina</creatorcontrib><creatorcontrib>Milisenda, Jose C.</creatorcontrib><creatorcontrib>Cid, Maria C.</creatorcontrib><creatorcontrib>Mascaró, Jose M.</creatorcontrib><creatorcontrib>Blanco, Isabel</creatorcontrib><creatorcontrib>Barberá, Joan Albert</creatorcontrib><creatorcontrib>Sibila, Oriol</creatorcontrib><creatorcontrib>Gratacos-Ginès, Jordi</creatorcontrib><creatorcontrib>Adán, Alfredo</creatorcontrib><creatorcontrib>Agustí, Alvaro</creatorcontrib><creatorcontrib>Sanmartí, Raimon</creatorcontrib><creatorcontrib>Panés, Julian</creatorcontrib><creatorcontrib>Cervera, Ricard</creatorcontrib><creatorcontrib>Vila, Jordi</creatorcontrib><creatorcontrib>Soriano, Alex</creatorcontrib><creatorcontrib>Gómez-Puerta, José A.</creatorcontrib><creatorcontrib>Immunocovid Clinic</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of autoimmunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarmiento-Monroy, Juan C.</au><au>Espinosa, Gerard</au><au>Londoño, Maria-Carlota</au><au>Meira, Fernanda</au><au>Caballol, Berta</au><au>Llufriu, Sara</au><au>Carrasco, Josep Lluis</au><au>Moll-Udina, Aina</au><au>Quintana, Luis F.</au><au>Giavedoni, Priscila</au><au>Ramírez, Julio</au><au>Inciarte-Mundo, Jose</au><au>Solana, Elisabeth</au><au>Blanco, Yolanda</au><au>Martinez-Hernandez, Eugenia</au><au>Sepúlveda, Maria</au><au>Llorenç, Victor</au><au>Prieto-González, Sergio</au><au>Espígol-Frigolé, Georgina</au><au>Milisenda, Jose C.</au><au>Cid, Maria C.</au><au>Mascaró, Jose M.</au><au>Blanco, Isabel</au><au>Barberá, Joan Albert</au><au>Sibila, Oriol</au><au>Gratacos-Ginès, Jordi</au><au>Adán, Alfredo</au><au>Agustí, Alvaro</au><au>Sanmartí, Raimon</au><au>Panés, Julian</au><au>Cervera, Ricard</au><au>Vila, Jordi</au><au>Soriano, Alex</au><au>Gómez-Puerta, José A.</au><aucorp>Immunocovid Clinic</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center</atitle><jtitle>Journal of autoimmunity</jtitle><addtitle>J Autoimmun</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>117</volume><spage>102580</spage><epage>102580</epage><pages>102580-102580</pages><artnum>102580</artnum><issn>0896-8411</issn><issn>1095-9157</issn><eissn>1095-9157</eissn><abstract>There is increasing interest regarding SARS-CoV-2 infection in patients with autoimmune and immune-mediated inflammatory diseases (AI/IMID) with some discrepancies in different cohorts about their risk and outcomes. The aim was to describe a multidisciplinary cohort of patients with AI/IMID and symptomatic SARS-CoV-2 infection in a single tertiary center and analyze sociodemographic, clinical, and therapeutic factors associated with poor outcomes. A retrospective observational study was conducted from the 1st of March until May 29th, 2020 in a University tertiary hospital in Barcelona, Spain. Patients with an underlying AI/IMID and symptomatic SARS-CoV-2 infection were identified in our local SARS-CoV-2 infection database. Controls (2:1) were selected from the same database and matched by age and gender. The primary outcome was severe SARS-CoV-2 infection, which was a composite endpoint including admission to the intensive care unit (ICU), need for mechanical ventilation (MV), and/or death. Several covariates including age, sex, and comorbidities among others were combined into a multivariate model having severe SARS-CoV-2 as the dependent variable. Also, a sensitivity analysis was performed evaluating AID and IMID separately. The prevalence of symptomatic SARS-CoV-2 infection in a cohort of AI/IMID patients was 1.3%. Eighty-five patients with AI/IMID and symptomatic SARS-CoV-2 were identified, requiring hospitalization in 58 (68%) cases. A total of 175 patients admitted for SARS-CoV-2 (58 with AI/IMID and 117 matched-controls) were analyzed. In logistic regression analysis, a significant inverse association between AI/IMID group and severe SARS-CoV-2 (OR 0.28; 95% CI 0.12–0.61; p = 0.001), need of MV (OR 0.20; IC 95% 0.05–0.71; p = 0.014), and ICU admission (OR 0.25; IC 95% 0.10–0.62; p = 0.003) was found. Patients with AI/IMID who require admission for SARS-CoV-2 infection have a lower risk of developing severe disease, including the need to stay in the ICU and MV. •Patients with AI/IMID fwho required admission for SARS CoV2 infection have a lower risk of developing severe disease.•Among patients with AID and IMID, there were no differences in terms of severity.•According to the 7-category ordinal scale, maximum oxygen requirement was lower among AI/IMID group.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33338707</pmid><doi>10.1016/j.jaut.2020.102580</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8177-702X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0896-8411
ispartof Journal of autoimmunity, 2021-02, Vol.117, p.102580-102580, Article 102580
issn 0896-8411
1095-9157
1095-9157
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7836738
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Adverse outcome
Aged
Autoimmune diseases
Autoimmune Diseases - epidemiology
Autoimmune Diseases - mortality
Cohort Studies
COVID-19
COVID-19 - epidemiology
COVID-19 - mortality
Female
Hospitalization - statistics & numerical data
Humans
Immunosuppression
Intensive Care Units - statistics & numerical data
Interdisciplinary Communication
Male
Middle Aged
Prevalence
Registries
Respiration, Artificial - statistics & numerical data
Retrospective Studies
Risk Factors
SARS-CoV-2 - physiology
Severe acute respiratory syndrome coronavirus 2
Spain - epidemiology
Survival Analysis
Treatment Outcome
title A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T12%3A00%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20multidisciplinary%20registry%20of%20patients%20with%20autoimmune%20and%20immune-mediated%20diseases%20with%20symptomatic%20COVID-19%20from%20a%20single%20center&rft.jtitle=Journal%20of%20autoimmunity&rft.au=Sarmiento-Monroy,%20Juan%20C.&rft.aucorp=Immunocovid%20Clinic&rft.date=2021-02-01&rft.volume=117&rft.spage=102580&rft.epage=102580&rft.pages=102580-102580&rft.artnum=102580&rft.issn=0896-8411&rft.eissn=1095-9157&rft_id=info:doi/10.1016/j.jaut.2020.102580&rft_dat=%3Cproquest_pubme%3E2471461730%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471461730&rft_id=info:pmid/33338707&rft_els_id=S0896841120302134&rfr_iscdi=true